On August 27th, Southern Finance and Economics reported that the news of Sanofi's Pasteur flu vaccine being suspended or urgently recalled circulated online last night. In response, Sanofi told 21st Century Business Herald reporters that flu vaccine products themselves are highly complex. During the ongoing stability assessment process, Sanofi observed the flu vaccine Valin&B for the 2024-2025 flu season; reg; 、 Vernier& reg; The potency (relevant reference data for the expected biological effects of vaccines) shows a downward trend. We anticipate that the efficacy of the vaccine may be affected before the end of the product's shelf life. As a preventive measure, Sanofi has decided to temporarily suspend the supply and sale of these vaccines in China.
The flu vaccine Valin, which has been launched and circulated for use this year; reg;、 Vernier& reg; All have been approved for listing, strictly comply with various laws and regulations, national drug standards, and legal requirements, and meet the release standards. No signs or evidence have been found to affect the safety and effectiveness of the product. The decision to temporarily suspend the supply and sale of these vaccines in China is only a preventive measure. (21st Century Business Herald)